Burden of typhoid fever and cholera: similarities and differences. Prevention strategies for European travelers to endemic/epidemic areas

D Amicizia, R T Micale, B M Pennati, F Zangrillo, M Iovine, E Lecini, F Marchini, P L Lai, D Panatto, D Amicizia, R T Micale, B M Pennati, F Zangrillo, M Iovine, E Lecini, F Marchini, P L Lai, D Panatto

Abstract

The burden of diarrheal diseases is very high, accounting for 1.7 to 5 billion cases per year worldwide. Typhoid fever (TF) and cholera are potentially life-threatening infectious diseases, and are mainly transmitted through the consumption of food, drink or water that have been contaminated by the feces or urine of subjects excreting the pathogen. TF is mainly caused by Salmonella typhi, whereas cholera is caused by intestinal infection by the toxin-producing bacterium Vibrio cholerae. These diseases typically affect low- and middle-income countries where housing is overcrowded and water and sanitation are poor, or where conflicts or natural disasters have led to the collapse of the water, sanitation and healthcare systems. Mortality is higher in children under 5 years of age. Regarding their geographical distribution, TF has a high incidence in sub-Saharan Africa, India and south-east Asia, while cholera has a high incidence in a few African countries, particularly in the Horn of Africa and the Arabian Peninsula. In the fight against these diseases, preventive measures are fundamental. With modern air travel, transmissible diseases can spread across continents and oceans in a few days, constituting a threat to global public health. Nowadays, people travel for many reasons, such as tourism and business. Several surveys have shown that a high proportion of travelers lack adequate information on safety issues, such as timely vaccination and prophylactic medications. The main objective of this overview is to provide information to help European travelers to stay healthy while abroad, and thus also to reduce the potential importation of these diseases and their consequent implications for public health and society. The preventive measures to be implemented in the case of travel to countries where these diseases are still endemic are well known: the adoption of safe practices and vaccinations. It is important to stress that an effective preventive strategy should be based both on vaccinations and on hygiene travel guidelines. Furthermore, the emergence of multidrug-resistant strains is becoming a serious problem in the clinical treatment of these diseases. For this reason, vaccination is the main solution.

Keywords: Cholera; Cholera vaccines; International travel; Salmonella Typhi; Travel medicine; Typhoid fever vaccines.

©2019 Pacini Editore SRL, Pisa, Italy.

Figures

Fig. 1.
Fig. 1.
Typhoid incidence in low- and middle-income countries (risk-adjusted and corrected for blood culture sensitivity), adapted from Mogasale et al. [19]. Colors indicate different incidence values, with darker shades corresponding to higher incidence.
Fig. 2.
Fig. 2.
Incidence in the Global Burden of Disease regions and sub-regions made up of low- and middle-income countries. The incidence is per 100,000 person-years. Adapted from Antillón et al. [20].
Fig. 3.
Fig. 3.
Countries reporting cholera cases in 2017 (Adapted from WHO, 2018) [67]. The colors indicate different values of incidence; a darker shade corresponds to a higher incidence.

References

    1. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017;17:909-48. 10.1016/S14733099(17)30276-1
    1. CDC. Newton AE, Routh JA, Mahon BE. Infectious Diseases Related Travel. Chapter 3. Typhoid & Paratyphoid fever. Available at: [Accessed on 30/05/2019].
    1. Popoff MY, Bockemühl J, Gheesling LL. Supplement 2002 (no. 46) to the Kauffmann-White scheme. Res Microbiol 2004;155:568-70.
    1. World Health Organization (WHO). Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines. Available at: [Accessed on 21/02/2019].
    1. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 2015;28:901-37. 10.1128/CMR.00002-15
    1. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2014;(1):CD001261 10.1002/14651858.CD001261.pub3
    1. CDC. Health information for international travel. The yellow book 2016. Oxford University Press; Available at: [Accessed on 30/05/2019].
    1. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010;50:241-6. 10.1086/649541
    1. World Health Organization. The diagnosis, treatment and prevention of typhoid fever. WHO/V&B/03.17. Geneva, Switzerland: WHO, 2003.
    1. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005;366:749-62.
    1. Maskey AP, Day JN, Tuan PQ, Thwaites GE, 2, Campbell JI, Zimmerman M, Farrar J, Basnyat B. Salmonella enterica Serovar Paratyphi A and S. enterica Serovar typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clinical Infectious Diseases 2006;42:1247-53.
    1. CDC. Health information for international travel. The yellow book 2016. Oxford University Press; Available at: [Accessed on 20/01/2017].
    1. Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AK. Challenges and opportunities for typhoid fever control: a call for coordinated action. Clin Infect Dis 2016;62(Suppl 1):S4-8. 10.1093/cid/civ976
    1. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019;19:369-81. 10.1016/S1473-3099(18)30685-6
    1. Buckle GC, Walker CL, Black RE. Typhoid fever and para- typhoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2:010401 10.7189/jogh.02.010401
    1. Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleess-chauwer B, Döpfer D, Fazil A, Fischer-Walker CL, Hald T, Hall AJ, Keddy KH, Lake RJ, Lanata CF, Torgerson PR, Havelaar AH, Angulo FJ. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS Med 2015;12:e1001921 10.1371/journal.pmed.1001921 eCollection 2015
    1. Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. Lancet 2015;385:1136-45. 10.1016/S0140-6736(13)62708-7
    1. Prüss-Ustün A, Bartram J, Clasen T, Colford JM, Jr, Cumming O, Curtis V, Bonjour S, Dangour AD, De France J, Fewtrell L, Freeman MC, Gordon B, Hunter PR, Johnston RB, Mathers C, Mäusezahl D, Medlicott K, Neira M, Stocks M, Wolf J, Cairncross S. Burden of disease from inadequate water, sanitation and hygiene in low- and middle-income settings: a retrospective analysis of data from 145 countries. Trop Med Int Health 2014;19:894-905. Epub 2014 Apr 30. 10.1111/tmi.12329
    1. Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, Kim YE, Park JK, Wierzba TF. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health 2014;2:e570-80. 10.1016/S2214-109X(14)70301-8
    1. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, Marks F, Pitzer VE. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLoS Negl Trop Dis 2017;11:e0005376 10.1371/journal.pntd.0005376
    1. Marchello CS, Hong CY, Crump JA. Global typhoid fever incidence: a systematic review and meta-analysis. Clin Infect Dis 2019;68(S2):S105-16. 10.1093/cid/ciy1094
    1. Franco-Paredes C, Khan MI, Gonzalez-Diaz E, Santos-Preciado JI, Rodriguez-Morales AJ, Gotuzzo E. Enteric fever: a slow response to an old plague. PLoS Negl Trop Dis 2016;10:e0004597 10.1371/journal.pntd.0004597
    1. Amicizia D, Arata L, Zangrillo F, Panatto D, Gasparini R. Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®). J Prev Med Hyg 2017;58:E1-E8.
    1. Levine MM. Typhoid fever vaccines. Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed Philadelphia, PA: Elsevier Saunders; 2012, pp. 812-36.
    1. AIFA. Summary of the product Characteristic. Available at: . [Accessed on 23/07/2019].
    1. Nisini R, Biselli R, Matricardi PM, Fattorossi A, D’Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine 1993;11:582-6.
    1. Cryz SJ, Vanprapar N, Jr, Thisyakorn U, Olanratmanee T, Losonsky G, Levine MM, Chearskul S. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infection Immunity 1993;61:1149-51.
    1. Gilman RH, Hornick RB, Woodard WE, DuPont HL, Snyder MJ, Levine MM, Libonati JP. Evaluation of a UDP-glucose- 4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis.1977;136:717-23.
    1. Wahdan MH, Serie C, Germanier R, Lackany A, Cerisier Y, Guerin N, Sallam S, Geoffroy P, el Tantawi AS, Guesry P. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization 1980;58:469-74.
    1. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;1:1049-52.
    1. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999;17(Suppl 2):S22-27.
    1. Bhuiyan TR, Choudhury FK, Khanam F, Saha A, Sayeed MA, Salma U, Lundgren A, Sack DA, Svennerholm AM, Qadri F. Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh. Vaccine 2014;32:1055-60. 10.1016/j.vaccine.2014.01.001
    1. Jackson BR, Iqbal S, Mahon B; Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of typhoid vaccine - Advisory Committee on Immunization Practices, United States, 2015. MWR Morb Mortal Wkly Rep 2015;64:305-8.
    1. Date KA, Bentsi-Enchill A, Marks F, Fox K. Typhoid fever vaccination strategies. Vaccine 2015;33(Suppl 3):C55-61. 10.1016/j.vaccine.2015.04.028
    1. FDA Typhoid VI polysaccharide vaccine Typhim vi®. Available at [Accessed on 20/02/2019].
    1. Acharya IL1 Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 1987;317:1101-4.
    1. Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M, Goudeau A, Levine MM. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986;154:342-5.
    1. Kaper JB, Morris JG, Levine MM. Cholera. Clin Microbiol Rev 1995;8:48-86.
    1. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 1998;62:1301-14.
    1. Clemens JD. Cholera vaccines. Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 7th edition Philadelphia, PA: WB Saunders Company; 2017, Chapter 14.
    1. Mukhopadhyay AK, Takeda Y, Nair GB. Cholera outbreaks in the El Tor biotype era and the impact of the new El Tor variants. Curr Top Microbiol Immunol 2014;379:17-47.
    1. Faruque AS, Fuchs GJ, Albert MJ. Changing epidemiology of cholera due to Vibrio cholerae O1 and O139 Bengal in Dhaka, Bangladesh. Epidemiol Infect 1996;116:275-8.
    1. Siddique AK, Zaman K, Akram K, Mutsuddy P, Eusof A, Sack RB. Emergence of a new epidemic strain of Vibrio cholerae in Bangladesh. An epidemiological study. Trop Geogr Med 1994;46:147-50.
    1. Grim CJ, Hasan NA, Taviani E, Haley B, Chun J, Brettin TS, Bruce DC, Detter JC, Han CS, Chertkov O, Challacombe J, Huq A, Nair GB, Colwell RR. Genome sequence of hybrid Vibrio cholera O1 MJ-1236, B-33, and CIRS101 and comparative genomics with V. cholerae. J Bacteriol 2010;192:3524-33.
    1. Kanungo S, Sah BK, Lopez AL, Sung JS, Paisley AM, Sur D, Clemens JD, Nair GB. Cholera in India: an analysis of reports, 1997-2006. Bull World Health Organ 2010;88:185-91.
    1. Siddique AK, Nair GB, Alam M, Sack DA, Huq A, Nizam A, Longini IM, Qadri F, Faruque SM, Colwell RR, Ahmed S, Iqbal A, Bhuiyan NA, Sack RB. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect. 2010;138:347-52.
    1. Piarroux R, Barrais R, Faucher B, Haus R, Piarroux M, Gaudart J, Magloire R, Didier R. Understanding the Cholera Epidemic, Haiti. Emerg Infect Dis 2011;17:1161-7.
    1. Conner JG, Teschler JK, Jones CJ, Yildiz FH. Staying alive: vibrio cholerae’s cycle of environmental survival, transmission, and dissemination. Microbiol Spect. 2016;4(2). 10.1128/microbiolspec
    1. Barr AJ. The biochemical basis of disease. Essays Biochem 2018;62:619-42. 10.1042/EBC20170054
    1. Cholera vaccines: WHO position paper – August 2017. Wkly Epidemiol Rec 201;92:477-98.
    1. Charles RC, Ryan ET. Cholera in the 21st century. Curr Opin Infect Dis 2011;24:472-7.
    1. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. Lancet 2017;390:1539-49. 10.1016/S0140-6736(17)30559-7
    1. Chowdhury F, Khan AI, Harris JB, LaRocque RC, Chowdhury MI, Ryan ET, Faruque ASG, Calderwood SB, Qadri F. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis J 2008;27:986-92.
    1. Harris JB, Khan AI, LaRocque RC, Dorer DJ, Chowdhury F, Faruque ASG, Sack DA, Ryan ET, Qadri F, Calderwood SB. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005;73:7422–7.
    1. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, Ryan ET, Qadri F, Calderwood SB. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2008;2:e221 10.1371/journal.pntd.0000221
    1. Holmner A, Mackenzie A, Krengel U. Molecular basis of cholera blood-group dependence and implications for a world characterized by climate change. FEBS Lett 2010;584:2548-55.
    1. Hannah G. Davies, Conor Bowman, Stephen P. Luby. Cholera − management and prevention. J Infect 2017;74: S66-S73.
    1. Watson JT, Gayer M, Connolly MA. Epidemics after natural disasters. Emerg Infect Dis 2007;13:1-5.
    1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 2015;9:e0003832 10.1371/journal.pntd.0003832
    1. WHO (2014) Cholera surveillance and number of cases. Geneva: World Health Organization.
    1. Griffith DC, Kelly-Hope LA, Miller MA. Review of reported cholera outbreaks worldwide, 1995-2005. Am J Trop Med Hyg 2006;75:973-7.
    1. Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 2007;7:521-30.
    1. Masuet Aumatell C, Ramon Torrell JM, Zuckerman JN. Review of oral cholera vaccines: efficacy in young children. Infect Drug Resist 2011;4:155-60. 10.2147/IDR.S10339
    1. Legros D; Partners of the Global Task Force on Cholera Control. Global cholera epidemiology: opportunities to reduce the burden of cholera by 2030. J Infect Dis 2018;218(suppl_3):S137-S140. 10.1093/infdis/jiy486
    1. Hamilton KL., Robert K. Crane-Na(+)-glucose cotransporter to cure? Front Physiol 2013;4:53.
    1. Dutta D, Chowdhury G, Pazhani GP, Guin S, Dutta S, Ghosh S, Rajendran K, Nandy RK, Mukhopadhyay AK, Bhattacharya MK, Mitra U, Takeda Y, Nair GB, Ramamurthy T. Vibrio cholerae non-O1, non-O139 serogroups and cholera-like diarrhea, Kolkata, India. Emerging Infect Dis 2013;19:464-7.
    1. World Health Organization. Cholera, 2017. Wkly Epidemiol Rec 2018;93:489-500.
    1. Communicable Disease Threats Report Week 38, 16-22 September 2018.
    1. World Health Organization. Communicable diseases following natural disasters [Internet]. 1211 Geneva 27 Switzerland; 2006. Report No.: WHO/CDS/NTD/DCE/2006.4. Available at: . [Accessed on 30/03/2019].
    1. Jutla A, Khan R, Colwell R. Natural disasters and cholera outbreaks: current understanding and future outlook. Curr Environ Health Rep 2017;4:99-107. 10.1007/s40572-017-0132-5
    1. Outbreak surveillance and response in humanitarian emergencies WHO guidelines for EWARN implementation. Geneva, 2012.
    1. Amar PK. Ensuring safe water in post-chemical, biological, radiological and nuclear emergencies. J Pharm Bioallied Sci 2010;2:253-66. 10.4103/0975-7406.68508
    1. Hove-Musekwa SD, Nyabadza F, Chiyaka C, Das P, Tripathi A, Mukandavire Z. Modelling and analysis of the effects of malnutrition in the spread of cholera. Mathematical and Computer Modelling 2011;53:1583-95. 10.1016/j.mcm.2010.11.060
    1. Cholera: risk factors. Available at: . [Accessed 20/02/2019].
    1. Gaffga NH, Tauxe RV, Mintz ED. Cholera: a new homeland in Africa? Am J Trop Med Hyg 2007;77:705-13.
    1. Alam M, Hasan NA, Sadique A, Bhuiyan NA, Ahmed KU, Nusrin S, Nair GB, Siddique AK, Sack RB, Sack DA, Huq A, Colwell RR. Seasonal cholera caused by Vibrio cholerae serogroups O1 and O139 in the coastal aquatic environment of Bangladesh. Appl Environ Microbiol 2006;72:4096-104. 10.1128/AEM.00066-06
    1. Singleton FL, Attwell RW, Jangi MS, Colwell RR. Influence of salinity and organic nutrient concentration on survival and growth of Vibrio cholerae in aquatic microcosms. Appl Environ Microbiol 1982;43:1080-5.
    1. Lara RJ, Neogi SB, Islam MS, Mahmud ZH, Yamasaki S, Nair GB. Influence of catastrophic climatic events and human waste on vibrio distribution in the Karnaphuli Estuary, Bangladesh. Eco Health 2009;6:279 10.1007/s10393-009-0257-6
    1. Leaning J, Guha-Sapir D. Natural disasters, armed conflict, and public health. N Engl J Med 2013;369:1836-42. 10.1056/NEJMra1109877
    1. McMichael A. Human population health: sentinel criterion of environmental sustainability. Curr Opin Environ Sustain. 2009;1:101-6. 10.1016/j.cosust.2009.07.001
    1. EM DAT. The OFDA/CRED International Disaster Database [Internet]. 2016. Available at: [Accessed on 30/03/2019].
    1. EMA. Summary of the product Characteristic. Available at: . [Accessed on 20/02/2019].
    1. Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009;27:1433-9. 10.1016/j.vaccine.2008.12.036
    1. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Stanton BF, Kay BA, Khan MU, Yunus M, Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986;2:124-7. 10.1016/S0140-6736(86)91944-6
    1. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005;352:757-67.
    1. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005;366:44-9.
    1. Longini IM, Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med 2007;4:e336.
    1. Jonker EFF, Uijlings MAC, Visser LG, Soonawala D. Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial. Vaccine 2019;37:3133-9. 10.1016/j.vaccine.2019.04.010
    1. Clemens JD, Harris JR, Sack DA, Chakraborty J, Ahmed F, Stanton BF, et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 1988;158:60–9. 10.1093/infdis/158.1.60
    1. Jeline T, Kollaritsch H. Vaccination with Dukoral against travelers’ diarrhea (ETEC) and cholera. Expert Rev Vaccines 2008;7:561-7. 10.1586/14760584.7.5.561
    1. WHO Water, sanitation and hygiene interventions and the prevention of diarrhea. Available at . [Accessed on 22/03/2019].
    1. WHO Guidelines on sanitation and health. Available at: [Accessed on 30/03/2019].
    1. Tagliabue A, Rappuoli R. Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. Front Immunol 2018; 9:1068 10.3389/fimmu.2018.01068
    1. Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O’Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Ste-vens K, Whitehead S, Barrell BG. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001;413:848-52.
    1. WHO. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008;83:49-59.
    1. . Available at: .
    1. Kitaoka M, Miyata ST, Unterweger D, Pukatzki S. Antibiotic resistance mechanisms of Vibrio cholerae. J Med Microbiol 2011;60(Pt 4):397-407. 10.1099/jmm.0.023051-0
    1. Saulat J. Cholera - Epidemiology, Prevention and Control 2016 Capter 6. 10.5772/63358
    1. Epicentro. Salute in viaggio. Available at: . [Accessed on 22/03/2019].
    1. World Tourism Organization and Global Tourism Economy Research Centre (2018), UNWTO/GTERC Asia Tourism Trends – 2018 Edition, UNWTO, Madrid, DOI: 10.18111/9789284420032
    1. Van Herck K, Zuckerman J, Castelli F, Van Damme P, Walker E, Steffen R; European Travel Health Advisory Board. Travelers’ knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med 2003;10:75-8.
    1. Statement on international travelers and typhoid: an Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT). Available at: [Accessed on 22/02/2019].
    1. Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5:623-8.
    1. Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med 2005;142: 67-72.
    1. Awofeso N, Aldabk K. Cholera, migration, and global health – a critical review. Int J Travel Med Glob Health 2018;6:92-9. 10.15171/ijtmgh.2018.19
    1. International travel health guide 2019 online edition. Disponibile all’indirizzo: . [ultimo accesso 27/11/2019.
    1. Kozicki M, Steffen R, Schar M. ‘Boil it. Cook it. Peel it or forget it’: does this rule prevent travellers’ diarrhoea? Int J Epidemiol 1985;14:169-72.
    1. Van Herck K, Van Damme P, Castelli F, Zuckerman J, Nothdurft H, Dahlgren AL, Gisler S, Steffen R, Gargalianos P, Lopéz-Vélez R, Overbosch D, Caumes E, Walker E. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 2004;11:3-8.
    1. Leggat PA. Sources of health advice given to travelers. J Travel Med 2000;7:85-8.
    1. Lee TK, Hutter JN, Masel J, Joya C, Whitman TJ. Guidelines for the prevention of travel-associated illness in older adults. Trop Dis Travel Med Vaccines. 2017;3:10.
    1. Flaherty GT, Rossanese A, Steffen R, Torresi J. A golden age of travel: advancing the interests of older travellers. J Travel Med 2018;25(1).
    1. Han CT, Flaherty G. Profile of travelers with preexisting medical conditions attending a specialist travel medicine clinic in Ireland. J Travel Med 2015;22:312-7.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi